The development of novel compounds to seed a neurodegeneration drug discovery programme

新型化合物的开发为神经退行性疾病药物发现计划奠定了基础

• 批准号: 133353
• 金额: $ 13.3万
• 依托单位: UBIQUIGENT LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133353
• 关键词: development; novel; compounds; seed; neurodegeneration

With a growing and ageing population, the burden of chronic diseases is the UK’s greatest societal challenge. Thus there is an urgent need for new medicines to address the increasing impact on the population of chronic neurodegenerative diseases, including Parkinson’s, Alzheimer’s, Huntington’s and Amyotrophic Lateral Sclerosis that lead to dementia, movement and other disorders. Around 850,000 people in the UK suffer from dementia alone, costing the healthcare system >£26bn per year. Very few treatments are currently available for people with neurodegenerative diseases, and those that do exist treat the symptoms or are effective at only certain disease stages. A drug target has been identified whose targeting has the potential for the treatment of such diseases. The objective of this project is to develop and characterise early chemical starting points that could form the basis of a programme towards the development of clinical drug candidates and ultimately potential treatments for a variety of both central and peripheral neurodegenerative diseases.

随着人口的不断增长和老龄化，慢性病的负担是英国最大的社会挑战。因此，迫切需要新的药物来解决慢性神经退行性疾病对人群的日益增加的影响，所述慢性神经退行性疾病包括帕金森氏病、阿尔茨海默氏病、亨廷顿氏病和肌萎缩性侧索硬化症，其导致痴呆、运动和其它病症。英国约有85万人患有痴呆症，每年花费医疗保健系统超过260亿英镑。目前很少有治疗方法可用于患有神经退行性疾病的人，并且那些确实存在的治疗症状或仅在某些疾病阶段有效。已经确定了一种药物靶标，其靶向具有治疗此类疾病的潜力。该项目的目标是开发和早期的化学起点，这些化学起点可以形成开发临床候选药物的方案的基础，并最终成为各种中枢和外周神经退行性疾病的潜在治疗方法。